-

04:46:57 PM

PRLD Stock News

PRLD - Prelude Therapeutics Inc

01/04/22 7:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13,

RHEA-AI

neutral

11/23/21 7:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Conference

RHEA-AI

neutral

11/12/21 8:00 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; Dose

RHEA-AI

neutral

11/08/21 9:00 AM

Nasdaq : PRLD

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug

RHEA-AI

neutral

10/07/21 9:00 AM

Nasdaq : PRLD

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients – – CDK9 inhibitor PRT2527 demonstrates strong

RHEA-AI

neutral

09/02/21 7:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19 th Annual Global

RHEA-AI

neutral

08/12/21 7:30 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – - Dose

RHEA-AI

neutral

07/19/21 7:00 AM

Nasdaq : PRLD

management

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotech

RHEA-AI

neutral

06/02/21 7:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: 42 nd Annual Goldman Sachs Global

RHEA-AI

neutral

05/11/21 7:30 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral

RHEA-AI

neutral

Prev 1 2 3 4 Next

PRLD Data

IndustryPharmaceutical Preparation Manufacturing
Websitepreludetx.com
Security namePrelude Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees122
Tags
- Health Technology
- Biotechnology

About Prelude Therapeutics Inc

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.